NCT00458367View on ClinicalTrials.gov

RiSPECT: Risperdal Safety Protocol Evaluation Consta Treatment, a Post Authorization Safety Survey to Obtain Information on the Safety and Efficacy of Risperidone When Used in Routine Clinical Practice

CompletedOBSERVATIONAL

Enrollment

5,296

Participants

Timeline

Start Date

June 30, 2002

Study Completion Date

October 31, 2006

Conditions

SchizophreniaPsychotic DisordersSchizoaffective Disorder

Interventions

DRUG

Open label risperidone long acting injectable

intramuscular injections every 2 weeks for 26 weeks, flexible dose 25 to 50 mg

All Listed Sponsors

lead

Janssen Pharmaceutica N.V., Belgium

INDUSTRY

NCT00458367 - RiSPECT: Risperdal Safety Protocol Evaluation Consta Treatment, a Post Authorization Safety Survey to Obtain Information on the Safety and Efficacy of Risperidone When Used in Routine Clinical Practice | Biotech Hunter | Biotech Hunter